New hope for Tough-to-Treat sarcomas: Triple-Drug attack enters testing
NCT ID NCT05253131
Summary
This study is testing a new combination of three drugs (selumetinib, ZEN-3694, and durvalumab) for people with advanced sarcomas that have not responded to standard treatments. The first part of the trial will find safe doses, and the second part will focus on a specific, aggressive type of nerve sheath tumor linked to a genetic condition called NF1. The goal is to see if this combination can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NF1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.